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Abstract  The  zika  virus,  another  re-emerging  Flavivirus  transmitted  to  humans  by  mosquitoes,
is responsible  for  the  most  recent  fever  outbreak  in  the  Americas  and  the  Paciﬁc,  starting  in
2015. The  immunologically  naïve  population  in  the  Americas  favors  the  spread  of  epidemics.  The
zika fever  is  characterized  by  febrile  illness,  malaise,  conjunctivitis  and  a  maculopapular  rash.
Similar to  other  arboviroses  recently  spread  in  the  Americas,  there  is  no  speciﬁc  or  effective
antiviral therapy  and  vaccines  are  still  in  trials.  The  only  effective  preventive  measures  consist
of individual  protection  against  mosquito  bites  and  vector  control.  This  febrile  illness  increases
the epidemiological  and  public  health  challenge  existing  in  America,  where  the  population  is
already ﬁghting  against  dengue  and  chikungunya  fever.  Disease  prevention  is  important  due  to
the economic  burden  it  entails.  The  fact  of  sexual  and  transfusion  virus  transmission  is  a  great
challenge to  overcome.  Doctors  need  to  distinguish  between  dengue,  chikungunya  and  other
diseases to  give  a  successful  treatment  and  prevent  the  disease  spreading.
© 2016  Published  by  Masson  Doyma  Me´xico  S.A.  on  behalf  of  Universidad  Auto´noma  de  Nuevo
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mong  many  public  health  alerts,  the  global  spread  of
rboviruses  is  of  concern  and  alarm.  The  Zika  virus  is  trans-
itted  to  people  through  the  bite  of  an  infected  mosquito
rom  the  Aedes  genus,  mainly  Aedes  aegypti  in  tropical
nd  subtropical  regions  and  Aedes  albopictus  in  temper-
te  climates.  These  are  the  same  mosquitoes  that  transmit
engue,  Chikungunya  and  yellow  fever.  The  disease  is  named
ika  virus  disease  (ZVD)  instead  of  Zika  fever  because  of
he  frequent  subfebril  and  afebrile  manifestations.  Last,
niversidad Auto´noma de Nuevo Leo´n. This is an open access article
y-nc-nd/4.0/).
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ut  not  least  important,  the  Zika  virus  is  the  third  recent
lobal  infectious  disease  outbreak,  following  closely  behind
1N1  ﬂu  and  the  Ebola  virus,  which  has  had  detrimental
mplications  for  pregnant  women  and  their  unborn  children.
pidemiology
he  ﬁrst  isolation  was  made  in  April  1947  from  the  serum
f  a  pyrexial  rhesus  monkey  in  the  canopy  of  Zika  for-
st,  Uganda,1 followed  by  an  isolation  from  Aedes  africanus
osquitoes  in  January  1948,  in  the  same  forest.  The  ﬁrst
uman  cases  were  detected  in  Uganda  and  the  United
epublic  of  Tanzania  in  1952,  where  neutralizing  antibodies
o  the  Zika  virus  were  detected  in  sera.2,3 A  couple  of  years
ater,  in  1954,  the  virus  was  isolated  from  a  girl  in  Eastern
igeria.4
From  the  1960s  to  the  1980s,  the  zika  virus  was  detected
n  mosquitoes  and  sentinel  rhesus  monkeys  in  countries  of
quatorial  Africa.  Sporadic  human  cases  were  identiﬁed,
ostly  by  serological  methods,  but  such  cases  were  rare  and
he  disease  was  regarded  as  benign.
In  1969,  the  Zika  virus  expanded  its  geographical  distri-
ution  in  equatorial  Asia,  where  it  is  the  ﬁrst  large  outbreak
n  humans  on  the  Paciﬁc  island  of  Yap,  in  the  Federated
tates  of  Micronesia.  An  estimated  73%  of  Yap  residents  over
hree  years  of  age  were  infected  with  the  Zika  virus.  No
eaths,  hospitalizations,  or  neurological  complications  were
eported.
From  2012  to  2014,  the  Zika  virus  caused  outbreaks
n  French  Polynesia,  Easter  Island,  Cook  Islands  and  New
aledonia.  Meanwhile,  the  virus  continued  circulating  in
ambodia,  Malaysia,  Thailand,  Nigeria,  Senegal  and  Uganda.
By  March  2015,  an  illness  characterized  by  a  skin  rash  was
etected  in  northern  Brazil.  Nevertheless,  it  was  not  until
ay  when  the  Zika  virus  infection  was  conﬁrmed.  By  July,
razil  reported  laboratory-conﬁrmed  Zika  cases  in  twelve
tates.  In  October  2015,  Colombia  reported  PCR-conﬁrmed
atients  with  locally  acquired  Zika  infections  and  poste-
iorly  156  conﬁrmed  cases  in  thirteen  municipalities.  The
ika  virus  was  limited  to  Brazil  and  Colombia  until  Novem-
er  2015,  when  it  spread  to  Suriname,  Guatemala,  Mexico,
l  Salvador,  Paraguay  and  Venezuela.  In  December,  Panama
eported  its  ﬁrst  conﬁrmed  cases,  as  well  as  Haiti,  Puerto
ico,  Martinique,  Honduras  and  French  Guiana.5
In  January  2016,  Bolivia  and  Saint  Martin  detected  their
rst  indigenous  cases,  as  well  as  Barbados,  U.S.  Virgin
slands,  Dominican  Republic,  Nicaragua  and  Jamaica.6 As
f  April  28,  2016,  the  new  countries  with  conﬁrmed  local
ransmissions  are:  Curacao,  Costa  Rica,  Republic  of  Trinidad
nd  Tobago,  Aruba,  Bonaire,  Sint  Maarten,  Saint  Vincent  and
he  Grenadines,  Dominica,  Cuba,  Saint  Lucia  and  Belize.
his  makes  a  total  of  35  countries/territories  with  ongoing
utochthonous  Zika  virus  transmission  and  7982  accumu-
ated  conﬁrmed  cases.7
In  Mexico,  the  ﬁrst  imported  case  was  identiﬁed  in
ovember  17,  2015,  when  a  traveler  came  back  from
olombia  to  Querétaro.  Later  in  that  month,  in  the  47th
pidemiological  Week,  the  ﬁrst  two  cases  were  reported  in
onterrey,  Nuevo  León,  and  in  Huixtla,  Chiapas.  None  of  the
atients  had  traveled  recently.8 New  cases  were  detected
ntil  the  52nd  Epidemiological  Week  in  Jalisco,  Chiapas  and
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uevo  León.9 The  ﬁrst  Epidemiological  Week  of  2016  lacked
onﬁrmed  cases.  However,  Chiapas  has  been  reporting  new
ases  since  the  2nd  Epidemiological  Week.10 Up  to  April  29,
016,  there  have  been  185  conﬁrmed  autochthonous  cases
n  Mexico  reported  from  the  states  of  Chiapas,  Guerrero,
alisco,  Michoacán,  Nayarit,  Nuevo  León,  Oaxaca,  Sinaloa,
abasco,  Veracruz  and  Yucatán.11
Even  though  there  is  no  autochthonous  ongoing  transmis-
ion  in  the  United  States,  the  presence  of  Ae.  albopictus
n  a  great  proportion  of  the  continental  US  poses  a  risk  for
utochthonous  Zika  virus  transmission.12 The  geographic  dis-
ribution  of  the  autochthonous  transmission  of  the  Zika  virus
an  be  observed  in  Fig.  1.
olecular virology
he  Zika  virus  is  a  member  of  the  Flavivirus  genus  of  the
laviviridae  family.  This  virus  is  related  to  other  pathogenic
ector  borne  Flavivirus,  where  we  can  ﬁnd  the  Dengue  virus,
he  West  Nile  Virus  and  the  Saint  Louis  encephalitis  virus.  It
s  a  single-stranded,  positive-sense,  RNA  virus  with  a  genome
pproximately  11  kb  in  length.13 The  single  open  reading
rame  (ORF)  encoding  a  polyprotein  is  framed  by  5′ and
′ untranslated  regions.  The  encoding  polyprotein  is  trans-
ated  and  processed  by  viral  and  cellular  proteases,  co-  and
ost-translationally,  into  three  structural  (capsid,  precursor
embrane  or  membrane,  and  envelope)  and  seven  nonstruc-
ural  (NS1,  NS2a,  NS2b,  NS3,  NS4a,  NS4b,  and  NS5)  proteins
Fig.  2).  The  NS1,  NS3  and  NS5  proteins  are  large  and  highly
onserved,  meanwhile  the  NS2A,  NS2B,  NS4A  and  NS4B  pro-
eins  are  small  and  hydrophobic.14
After  a  mosquito  bite,  the  Zika  virus  can  infect  human
ermal  ﬁbroblasts,  epidermal  keratinocytes  and  imma-
ure  dendritic  cells.  AXL,  a  phosphatydylserine  receptor,
as  been  described  as  a  ZIKV  entry  receptor  and  is  also
elated  with  cellular  autophagy,  enhancing  ZIKV  replication
n  permissive  cells.  DC-SIGN,  Tyro3  and  TIM-I  also  seem  to
ediate  ZIKV  entry.15 Information  concerning  ZIKV  replica-
ion  is  scarce;  therefore  we  present  the  common  features
f  the  Flaviviridae  family  life  cycle.  After  the  viral  parti-
le  interacts  with  the  host  receptors,  it  is  internalized  by
lathrin-mediated  endocytosis.  The  low  pH  of  the  endo-
ome  induces  fusion  of  the  virion  envelope  with  cellular
embranes.  Following  uncoating  of  the  nucleocapsid,  the
NA  genome  is  released  into  the  cytoplasm.  The  genome
erves  three  discrete  roles  within  its  life  cycle:  as  the  mes-
enger  RNA  (mRNA)  for  translation  of  all  viral  proteins,  a
emplate  during  RNA  replication,  and  the  genetic  material
ackaged  within  new  virus  particles.  RNA  replication  occurs
ntirely  in  the  cytoplasm  in  close  association  with  intracel-
ular  membranes.  Progeny  virions  assemble  by  budding  into
n  intracellular  membrane  compartment,  most  likely  the
ndoplasmic  reticulum  (ER),  then  transit  through  the  host
ecretory  pathway  and  are  released  at  the  cell  surface.16
Phylogenetic  analysis  among  the  genus  Flavivirus  places
IKV  at  clade  X,  with  the  Spondweni  virus,  in  the  mosquito-
orne  cluster.17 Recent  phylogenetic  analysis  divides  ZIKV
nto  three  different  lineages:  West  African,  East  African
nd  Asian.  The  three  distinct  ZIKV  lineages  share  a  com-
on  ancestor,  possibly  with  Ugandan  lineages  around  1920.18
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Figure  1  Countries  and  regions  in  the  Americas  with  autochthonous  Zika  virus  transmission  and  complications.  The  map  illus-
trates the  countries  and  regions  where  autochthonous  Zika  virus  transmission  is  taking  place.  It  also  shows  the  countries  where
Guillain--Barré  syndrome  cases  were  reported,  as  well  as  conﬁrmed  microcephaly  cases.  Mexico  and  Brazil  are  divided  by  states.
The Brazilian  state  names  are  in  italics.  Latin  and  Non  Caribbean  are  not  labeled  due  to  the  map  resolution.  Information  updated
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cApril 28,  2016.  ZIKV:  Zika  virus;  GBS:  Guillain--Barré  syndrome.
Source:  World  Health  Organization,52 Pan  American  Health  Orga
The  Asian  lineage  is  responsible  for  the  current  outbreak  in
America.19
TransmissionVector  transmission
The  Zika  virus  is  mostly  transmitted  to  people  through
the  bite  of  an  infected  mosquito  from  the  Aedes  genus,
a
A
tion,7 and  Secretarias  de  Saúde  dos  Estados  e  Distrito  Federal.46
ncluding  Aedes  aegypti  in  tropical  and  subtropical  regions
nd  Aedes  albopictus  in  temperate  regions.  Given  numerous
irus  isolations  from  mosquitoes,  they  are  clearly  the  natu-
al  reservoirs.  Vertebrate  hosts  are  most  likely  amplifying  or
ead-end  hosts,  since  no  vertebrate  in  nature  has  ever  been
onclusively  determined  to  serve  as  a  true  reservoir  for  any
rbovirus.20
Some  of  the  prevalent  vectors  identiﬁed  in  Africa  include
e.  luteocephalus, Ae.  africanus,  and  Ae.  furcifer.  Never-
heless,  the  dominant  species  varies  considerably  depending
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Figure  2  Zika  virus  genome  organization.  The  ﬁgure  shows  the  structural  and  nonstructural  proteins  the  way  they  are  organized
throughout the  genome  as  well  as  the  untranslated  regions  in  5′ and  3′.  The  name,  size  in  amino  acids  and  function  is  showed  for
each protein.  The  ﬁgure  is  drawn  to  scale  based  on  the  reference  ZIKV  genome  with  GenBank  access  number:  NC  012532.1.13 The
information regarding  viral  protein  function  was  obtained  from  the  UniProt  database  using  dengue  virus  due  to  the  lack  of  published
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ntranslated region;  Kb:  kilobases.
n  sampling  location.  Interestingly,  the  involvement  of  Ae.
egypti  has  been  small  in  Africa.21 On  the  other  hand,  Ae.
egypti  has  been  the  single  most  important  vector  in  South-
ast  Asia  and  the  Paciﬁc.  In  the  outbreak  on  Yap  Island  in  the
aciﬁc,  Ae.  hensilli  was  implicated  as  a  possible  vector.22
Ae.  albopictus  is  also  susceptible  to  infection  and  able
o  transmit  ZIKV.23 The  highest  concern  is  that  Ae.  albopic-
us  has  been  found  in  temperate  climates  where  Ae.  aegypti
s  absent,  allowing  virus  transmission  in  those  regions.  This
ncludes  37  of  48  contiguous  states  of  the  United  States
f  America,  Albania,  Bulgaria,  Croatia,  Southern  France,
reece,  Italy,  Malta,  Montenegro,  Slovenia,  Eastern  Spain,
nd  Southern  Switzerland.24,25
on-vector  transmission
ven  though  the  main  transmission  route  of  the  Zika  virus
s  by  the  bite  of  an  infected  mosquito,  cases  of  non-vector
ransmission  have  been  reported.
During  the  French  Polynesian  outbreak,  3%  of  1505
lood  donors,  asymptomatic  at  the  time  of  blood  dona-
ion,  were  found  positive  for  ZIKV  by  PCR.26,27 In  this  recent
utbreak,  two  possible  cases  of  transfusion--transmission
ave  been  described  in  Campinas,  Brazil  and  are  being
nvestigated.28 For  these  reasons,  the  Food  and  Drug  Admin-
stration  (FDA)  has  made  recommendations  to  prevent
ransfusion--transmission.  Some  of  these  recommendations
re:  defer  donors  at  risk  for  ZIKV  infections  for  4  weeks,
se  of  an  FDA-approved  pathogen  reduction  device,  and
est  local  blood  donations  with  an  FDA-licensed  blood  donor
creening  test  for  ZIKV  when  available.29 However,  a  recent
ublication  afﬁrmed  that  screening  potential  blood  donors
ased  on  symptoms  or  serological  testing  of  donated  blood
ould  do  little  to  protect  the  blood  supply,  reducing  the
isk  of  an  infected  donation  by  at  most  30%.  The  authors
dvise  that  high  incidence  areas  should  consider  PCR  testing
o  identify  safe  components  for  use  in  pregnant  women.30
In  addition,  the  Zika  virus  can  be  sexually  transmitted
rom  a  man  to  his  sex  partner(s).  During  February  2016,  the
DC  received  reports  of  14  instances  of  suspected  sexual
ransmission  of  the  Zika  virus.  Among  these,  two  laboratory-
onﬁrmed  cases  and  four  probable  cases  of  the  Zika  virus
t
T
o
ootein;  C:  capsid;  E:  envelope;  prM:  precursor  membrane;  UTR:
isease  have  been  identiﬁed  among  women  whose  only
nown  risk  factor  was  sexual  contact  with  a  symptomatic
ale  partner  with  recent  travel  to  an  area  with  ongoing  Zika
irus  transmission.31 To  date,  all  reported  cases  of  sexual
ransmission  of  the  Zika  virus  have  been  from  symptomatic
ale  partners.  Sexual  transmission  of  the  Zika  virus  from
nfected  women  to  their  sex  partners  and  from  persons
ho  are  asymptomatically  infected  has  not  been  reported.31
here  have  been  two  reports  of  replication-competent  Zika
irus  isolated  from  semen  at  least  2  weeks  after  onset  of
llness,  when  blood  plasma  specimens  were  negative  by  RT-
CR.32,33 Viral  ARN  has  been  detected  in  semen  by  RT-PCR  as
ong  as  62  days  after  illness  onset,  but  the  duration  of  persis-
ence  of  infectious  Zika  virus  in  semen  remains  unknown.34
here  is  now  a  report  that  indicates  that  the  Zika  virus  can  be
ransmitted  through  anal  sex,  as  well  as  vaginal  sex.35 There-
ore,  the  Centers  for  Disease  Control  and  Prevention  issued
nterim  guidance  for  the  prevention  of  sexual  transmission
f  the  Zika  virus.  Couples  in  which  a  woman  is  pregnant
hould  use  condoms  or  abstain  from  sex  for  the  duration
f  the  pregnancy.  Likewise,  couples  in  which  a  man  had  a
onﬁrmed  Zika  virus  infection  or  clinical  illness  should  con-
ider  using  condoms  or  abstaining  from  sex  for  at  least  6
onths  after  onset  of  illness.  If  the  couple  lives  in  an  area
ith  active  Zika  virus  transmission,  the  use  of  condoms  or
bstaining  from  sex  while  active  transmission  persists  are
ecommended.36 Evidence  implies  trans-placental  transmis-
ion  and  perinatal  transmission  during  delivery,  with  Zika
irus  RNA  being  found  in  amniotic  ﬂuid  and  in  paired  blood
amples  taken  from  newborn  infants  and  mothers.37,38 There
s  no  evidence  to  support  transmission  by  breastfeeding  or
ia  contact  with  saliva,  urine,  or  respiratory  droplets.
linical features
he  ﬁrst  clinical  characterizations  described  Zika  virus
nfections  as  mild  and  self-limiting.
After  an  experimentally  induced  Zika  virus  infection  in
 human  volunteer,  it  resembled  the  condition  observed  in
he  girl  in  Eastern  Nigeria  reported  by  MacNamara  closely.4
he  infection  was  a  short-term  fever,  without  evidence
f  involvement  of  any  particular  tissue.  In  both  cases  the
nly  manifestations  were  fever  and  headache.39 The  clinical
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Table  1  Differential  diagnostic  of  most  common  arbovirus  infections  in  acute  presentations.
Signs  and  symptoms  ZIKV  (%)  CHIKV  (%)  DENV  (%)  YFV  (%)  WNV  (%)
Fever  65  89  90.6  72  95
Headache 45  47  57.7  54  65
Myalgia 48  60  54.6  36  35
Arthralgia 65  96.1  37.5  ND  35
Arthritis Rare  31.8  3.8  ND  ND
Retroocular  pain  39  Rare  41.4  ND  ND
Non-purulent  conjunctivitis  55  Rare  7.7  ND  ND
Lymphadenopathy  45  8.9  Rare  ND  ND
Rash 90  40.1  7  ND  5
Signs of  bleeding Rare  6.4  8.3  36  ND
Neurologic signs Rare  12.1  6  ND  35
Nausea/vomit  10  47  32  30  45
Edema 19  Rare  14.4  ND  ND
Jaundice ND  ND  Rare  34  ND
22 72 73 74 75
 Riab 76
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ZIKV: Zika virus; CHIKV: chikungunya virus; DENV: dengue virus; Y
picture  of  the  infection  described  by  a  worker  that  was
infected  collecting  mosquitoes  in  the  Zika  forest  was  that
of  a  mild  febrile  illness  of  short  duration  accompanied  by
a  generalized  maculopapular  rash.40 In  Java,  Indonesia,  all
patients  had  high  fevers  upon  examination.  Six  of  seven
patients  had  stomach  ache,  ﬁve  had  malaise,  ﬁve  expe-
rienced  dizziness  and  four  were  anorexic.  Less  frequently
reported  symptoms  and  signs  were  diarrhea,  constipation,
hypotension  and  chills.  Interestingly,  arthralgia,  myalgia,
vomiting,  conjunctivitis,  hematuria,  lymphadenopathy  and
leg  pain  were  present  in  one  of  the  patients.  Furthermore,
none  of  the  patients  had  a  rash.41 At  a  study  made  in  Thai-
land  with  cases  from  2012  to  2014,  the  clinical  presentation
was  mild  and  nonspeciﬁc.  All  subjects  presented  fever  and  a
maculopapular  rash.  Other  symptoms  included  sore  throat,
arthralgia,  myalgia,  rhinorrhea,  and  headache.  Only  two
patients  complained  of  conjunctivitis,  which  was  less  than
the  rate  previously  reported  in  ZIKV  cases  outside  Africa.42
The  incubation  period  of  the  Zika  virus  disease  is  not
clear,  but  is  estimated  to  be  4--7  days.30 The  symptoms
are  similar  to  other  arbovirus  infections  such  as  dengue,
and  include  fever,  maculopapular  rash,  pruritus,  conjunc-
tival  hyperemia,  myalgia,  arthralgia,  malaise,  headache,
retro-orbital  pain  and  digestive  disorders.  These  symptoms
are  usually  mild  and  last  for  2--7  days.22,43 In  addition,
common  presentations  accompanying  the  febrile  illness  are
frequently  confused  with  dengue  virus  infection,  which  may
result  in  underreporting  of  Zika  virus  infection.  In  Table  1,
we  present  the  frequent  signs  and  symptoms  of  the  most
common  arboviroses.  This  can  be  of  great  help  to  clinicians
regarding  differential  diagnosis.
Complications
When  Zika  virus  infections  were  ﬁrst  noted,  there  were  no
reports  of  complications,  but  in  recent  ZIKV  outbreaks  the
incidence  of  neurological  disorders  has  increased.  Evidence
that  neurological  disorders,  including  microcephaly  and
Guillain--Barré  syndrome,  are  linked  to  Zika  virus  infection
b
i
fi.
llow fever virus; WNV: West Nile virus; ND: no data.
emains  circumstantial,  but  a  growing  body  of  clinical  and
pidemiological  data  points  toward  a  causal  role  for  the  Zika
irus.
icrocephaly
here  are  6  countries,  territories  and  areas  reporting
icrocephaly  cases  potentially  associated  with  Zika  virus
nfection.  These  are  Brazil,  Cabo  Verde,  Colombia,  French
olynesia,  Martinique,  and  Panama  (Fig.  1).44
According  to  the  Ministry  of  Health  of  Brazil,  from  Octo-
er  22,  2015  through  April  23,  2016,  there  have  been  reports
f  7228  suspected  cases  of  microcephaly  or  other  nervous
ystem  malformations  among  newborns  across  the  country.
his  contrasts  with  the  period  from  2001  to  2014,  when  an
verage  of  163  microcephaly  cases  was  recorded  nationwide
er  year.45 Up  to  April  23,  2016,  Brazil  Health  authorities
ave  reviewed  3518  cases,  49%  of  the  total.  They  iden-
iﬁed  1198  conﬁrmed  cases  of  microcephaly  and/or  other
entral  nervous  system  (CNS)  malformations  with  evidence
uggestive  of  congenital  infection,  and  discarded  2320.46
he  1198  conﬁrmed  microcephaly  cases  occurred  in  435
unicipalities  located  in  22  Brazilian  Federal  Units:  Alagoas,
ahia,  Ceará,  Maranhão,  Paraíba,  Pernambuco,  Piauí,  Rio
rande  Do  Norte,  Sergipe,  Espírito  Santo,  Minas  Gerais,  Rio
e  Janeiro,  Amapá,  Amazonas,  Pará,  Rondônia,  Distrito  Fed-
ral,  Goiás,  Mato  Grosso,  Mato  Grosso  Do  Sul,  Paraná,  and
io  Grande  Do  Sul.46 There  have  been  251  deaths  (includ-
ng  miscarriages  or  stillbirths)  reported  among  microcephaly
nd/or  CNS  malformation  cases.  Fifty-four  of  these  deaths
ere  conﬁrmed  as  having  microcephaly  and/or  CNS  mal-
ormation,  167  remain  under  investigation  and  30  were
iscarded.46 There  is  evidence  that  in  addition  to  micro-
ephaly,  there  may  be  a  link  between  Zika  virus  infection
nd  hydrops  fetalis  and  fetal  demise.47A  recent  article  reports  an  increase  in  congenital  cere-
ral  malformations  and  dysfunction  in  fetuses  and  newborns
n  French  Polynesia,  following  an  epidemic  of  the  Zika  virus,
rom  October,  2013  to  March,  2014.  A  retrospective  review
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dentiﬁed  19  cases,  including  eight  with  major  brain  lesions
nd  severe  microcephaly,  six  with  severe  cerebral  lesions
ithout  microcephaly  and  ﬁve  with  brainstem  dysfunction
ithout  visible  malformations.  Of  the  ﬁve-microcephaly
ases  that  were  tested  virologically,  viral  ARN  was  detected
y  RT-PCR  and  infectious  ZIKV  isolates  were  obtained  in
our.  When  interviewed,  the  mothers  of  four  cases  reported
linical  infection  in  the  ﬁrst  trimester  of  pregnancy.  The
emaining  mother  could  not  be  reached.48
A  case  series  of  pregnant  U.S.  women  that  traveled  to
ika  affected  areas  reported  that  infection  during  pregnancy
as  associated  with  a  range  of  outcomes,  including  early
regnancy  losses,  congenital  microcephaly,  and  apparently
ealthy  infants.  In  addition,  viral  RNA  was  detected  in  fetal
emains  of  early  pregnancy  loss,  amniocentesis  ﬂuid,  and
lacenta.49
On  March  30th,  Colombia  reported  50  live  births  with
icrocephaly  between  January  4th,  2016  and  March  20th,
016.  Of  the  50  cases  registered,  16  were  discarded  for
icrocephaly  with  suspected  association  with  the  Zika  virus.
f  the  remaining  34  cases,  two  were  ruled  out  for  not  meet-
ng  the  national  criteria  for  association  with  microcephaly  by
ika  virus.  The  remaining  cases  (32)  are  under  investigation.
o  far,  eight  of  these  32  cases  of  microcephaly  presented
ositive  Zika  virus  results  by  RT-PCR.44
A  recent  study  from  Pernambuco,  Brazil,  established  that
0  of  31  studied  microcephaly  cases  had  Zika-speciﬁc  IgM  in
heir  CSF.  Since  IgM  does  not  cross  either  the  placenta  barrier
r  the  blood--brain  barrier,  the  presence  of  IgM  in  the  CSF
ndicates  that  the  neonate  had  the  infection  in  the  CNS.  This
s  strong  evidence  that  microcephaly  was  a  consequence  of
ika  virus  infection.50
A  group  of  researchers  evaluated  the  available  data
egarding  ZIKV  and  microcephaly  using  criteria  that  have
een  proposed  for  the  assessment  of  potential  teratogens.
hey  concluded  that  there  is  a  causal  relationship  between
renatal  Zika  virus  infection  and  microcephaly  and  other
erious  brain  anomalies.51
The  link  between  ZIKV  infection  and  microcephaly
ecomes  stronger  with  every  new  case  report  published.
owever,  case  reports,  unlike  cohort  studies,  do  not  estab-
ish  a  causative  link  between  the  virus  and  microcephaly.
ore  research  is  needed  to  clearly  establish  the  relationship
etween  ZIKV  infection  and  microcephaly.
uillain--Barré syndrome
ccording  to  the  WHO,  during  2015  and  2016,  thirteen
ountries  and  territories  have  reported  an  increased  inci-
ence  of  Guillain--Barré  syndrome  (GBS)  and/or  laboratory
onﬁrmation  of  a  Zika  virus  infection  among  GBS  cases.52
Countries  where  there  is  increased  incidence  of  GBS
ases,  with  at  least  one  GBS  case  with  conﬁrmed  Zika
irus  infection  are:  Brazil,  Colombia,  Dominican  Republic,
l  Salvador,  French  Polynesia,  Honduras,  Suriname,  and
enezuela.  In  contrast,  the  countries  reporting  GBS  with
aboratory  conﬁrmed  Zika  virus  infections  without  increase
f  GBS  incidence  are:  French  Guiana,  Haiti,  Martinique,
anama  and  Puerto  Rico.52 Countries  or  territories  where
BS  cases  were  reported  can  be  seen  in  Fig.  1.
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There  is  little  information  in  respect  to  the  clinical  char-
cteristics  of  the  Guillain--Barré  syndrome  cases  caused
y  this  virus.  The  most  complete  description  is  from  a
ase-control  study  made  in  French  Polynesia,  where  they
iagnosed  42  cases  of  Guillain--Barré  syndrome.  Forty-one
98%)  patients  had  anti-Zika  virus  IgM  or  IgG,  and  all  (100%)
ad  neutralizing  antibodies  against  the  Zika  virus.53
Most  patients  had  electrophysiological  ﬁndings  compati-
le  with  the  acute  motor  axonal  neuropathy  (AMAN)  type  of
he  syndrome,  and  had  rapid  evolution  of  the  disease.53 The
linical  outcome  of  these  patients  with  the  Zika  virus  and
uillain--Barré  syndrome  was  generally  favorable,  despite
 rapid  onset  and  short  plateau  phase,  as  may  be  seen
n  other  patient  groups  suffering  from  the  AMAN  type  of
uillain--Barré  syndrome.  Even  though  it  is  very  likely  that
hese  patients  had  been  recently  infected  with  the  Zika
irus,  it  is  possible  that  the  disease  was  due  to  dengue  or
ight  possibly  have  been  unrelated  to  Flavivirus  infection.53
A  recent  case  report  showed  that  a  housekeeper  from
io  de  Janeiro  that  presented  clinical  features  consistent
ith  paraparetic  Guillain--Barré  syndrome,  had  a  positive
CR  test  for  ZIKV  in  serum,  cerebrospinal  ﬂuid,  saliva  and
rine.  It  is  noteworthy  that  the  patient’s  serum  and  cere-
rospinal  ﬂuid  were  negative  for  dengue  and  chikungunya  by
eal-time  PCR.54 This  study  helps  to  conﬁrm  the  association
etween  ZIKV  and  GBS.
Substantial  new  research  has  strengthened  the  associ-
tion  between  the  Zika  infection  and  the  occurrence  of
eurological  disorders.55 However,  more  investigation  is
eeded  to  better  understand  this  relationship.  Confound-
ng  factors  include  the  contemporary  circulation  of  dengue
nd  chikungunya  in  the  Americas,  which  are  transmitted  by
he  same  species  of  mosquito.
linical and laboratory diagnosis of Zika
ven  though  the  Zika  virus  was  discovered  decades  ago,
here  are  no  licensed  or  broadly  distributed  diagnostic  tests.
ccording  to  the  WHO,  a  suspected  case  of  Zika  virus  disease
s  deﬁned  as  a patient  with  a  rash  and  two  or  more  of  the
ollowing  signs  or  symptoms:  fever,  usually  <38.5 ◦C,  con-
unctivitis  (non-purulent/hyperemic),  arthralgia,  myalgia,
nd/or  peri-articular  edema.  A  arobable  case  of  Zika  virus
isease  is  a  patient  who  meets  the  criteria  of  a  suspected
ase  and  has  Zika  IgM  antibodies,  with  no  evidence  of  infec-
ion  with  other  ﬂaviviruses.  A  conﬁrmed  case  of  Zika  virus
isease  is  a  patient  who  meets  the  criteria  for  a suspected
ase  and  has  laboratory  conﬁrmation  of  recent  Zika  virus
nfection.  This  conﬁrmation  can  be  the  following:  viral  RNA
serum,  urine,  saliva,  tissue  or  whole  blood),  positive  Zika
gM  antibodies  and  plaque  reduction  neutralization  (PRNT90)
or  Zika  virus  titers  ≥20  and  four  (or  more)  times  greater
han  the  titers  for  other  ﬂaviviruses,  with  the  exclusion  of
ther  Flaviviruses.  In  autopsy  specimens,  detection  of  the
iral  genome  should  be  by  molecular  techniques,  or  antigen
etection  by  immunohistochemistry.56
Unfortunately,  if  the  Zika  virus  disease  is  suspected  in  a
opulation  where  other  ﬂaviviruses  are  endemic,  serolog-
cal  diagnosis  of  ZIKV  is  difﬁcult  to  interpret  because  the
igh  degree  of  cross-reactions  in  the  IgM  and  IgG  assays
ould  lead  to  false-positive  results.57 In  countries  where
The  Zika  virus  disease  121
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Figure  3  Diagnostic  algorithm  for  detecting  Zika  virus  and  related  arbovirus.  This  algorithm  is  adapted  from  the  one  proposed
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laboratory  capacities  are  limited,  the  arbovirus  diagnosis
is  often  performed  by  serologic  testing  by  IgM  ELISA  or
rapid  tests.  If  rapid  tests  are  used  for  dengue,  it  is  recom-
mended  to  use  a  combined  NS1  antigen  and  IgM  antibody  test
to  increase  the  sensitivity  and  speciﬁcity  of  dengue  fever
diagnosis.58 If  several  patients  are  negative  to  a  DENV  NS1
test  within  the  ﬁrst  week  of  a  ‘‘dengue-like  disease,’’  the
Zika  virus  disease  or  other  arboviruses  should  be  suspected.
In  countries  with  advanced  laboratory  capacities,  a  RT-PCR
assay  should  be  the  ﬁrst-line  test.  Patients  within  the  acute
phase  of  infection  with  a  dengue  or  chikungunya-like  syn-
drome,  or  fever  and  rash,  with  negative  DENV  and  CHIKV
RT-PCR  assays  should  be  tested  with  a  speciﬁc  ZIKV  RT-PCR
assay.57 The  algorithm  for  Zika  virus  detection  in  Fig.  3  can
be  a  useful  guide  for  clinicians.
There  are  two  strategies  for  the  molecular  detection
of  ZIKV.  One  is  the  detection  of  Flaviviruses  using  consen-
sus  primers  and  posterior  detection  of  speciﬁc  ZIKV  ARN.59The  other  strategy  is  to  use  speciﬁc  ZIKV  primers  and
probes.  Several  protocols  have  been  developed  to  target  the
E-encoding  gene,60 the  membrane-envelope  junction  (M/E-
encoding  gene),  the  partial  envelope  (pE)-encoding  gene,
c
(
b
en  secondary  Flavivirus  infections,  ELISA  for  IgM  against  Dengue
olymerase  chain  reaction;  DENV:  dengue  virus;  ZIKV:  Zika  virus;
nd  the  NS5-encoding  gene.61,62 Furthermore,  ZIKV  RT-PCR
o  not  cover  the  genetic  diversity  and  geographic  distri-
ution  of  all  ZIKV  strains.61 The  reason  is  that  the  primers
nd  probes  have  been  designed  using  only  the  few  full  ZIKV
enome  sequences  available.  On  March  17,  2016,  the  FDA
ssued  an  Emergency  Use  Authorization  (EUA)  to  authorize
he  emergency  use  of  the  CDC’s  Trioplex  Real-time  RT-PCR
ssay  for  the  qualitative  detection  and  differentiation  of
NA  from  the  Zika  virus,  dengue  virus,  and  chikungunya  virus
n  human  sera  or  cerebrospinal  ﬂuid,  and  for  the  qualitative
etection  of  Zika  virus  RNA  in  urine  and  amniotic  ﬂuid.63 On
pril  28,  2016,  Focus  Diagnostics,  Inc.’s  Zika  Virus  RNA  Qual-
tative  Real-Time  RT-PCR  test  was  authorized  under  the  EUA
or  the  qualitative  detection  of  RNA  from  the  Zika  virus  in
uman  serum  specimens.  This  is  the  ﬁrst  commercial  test  to
etect  the  Zika  virus  that  has  been  authorized  by  the  FDA
or  emergency  use.63
Zika  virus  serology  is  usually  performed  by  ELISA,  with
onﬁrmation  by  a  plaque  reduction  neutralization  test
PRNT,  which  is  the  ‘‘gold  standard’’  for  anti-Flavivirus  anti-
ody  differentiation)  according  to  standard  protocols.  How-
ver,  PRNT  is  done  only  in  highly  specialized  laboratories,
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s  expensive,  and  may  require  regulated  laboratories
ecause  of  the  manipulation  of  live  viruses.64 To  date,  there
s  no  validated  commercial  serology  kit  for  ZIKV,  but  on
ebruary  26,  2016,  the  FDA  issued  an  Emergency  Use  Autho-
ization  for  the  emergency  use  of  CDC  Zika  Immunoglobulin
 Antibody  Capture  Enzyme-Linked  Immunosorbent  Assay
Zika  MAC-ELISA)  for  the  presumptive  detection  of  Zika
irus-speciﬁc  IgM  in  human  sera  or  cerebrospinal  ﬂuid.63
amples  for  serologic  or  molecular  testing  should  have  spe-
ial  storage  conditions,  ranging  from  refrigeration  (2--8 ◦C)
o  freezing  (−10  to  −20 ◦C  or  −70 ◦C)  depending  of  the  time
nd  site  of  testing.65
reatment
imilar  to  other  arboviral  diseases,  there  is  no  speciﬁc
ntiviral  drug  treatment  for  ZIKV  infection.  Symptomatic
reatment  is  recommended  after  excluding  more  serious
onditions  like  malaria,  dengue,  and  bacterial  infections.  In
cute  infection,  treatment  is  symptomatic  and  supportive,
onsisting  of  rest  and  the  use  of  acetaminophen  to  relieve
ever  (<4  g/day).  The  use  of  ibuprofen,  naproxen,  or  another
on-steroidal  anti-inﬂammatory  agents  (NSAID)  to  relieve
he  arthritic  component  of  the  disease  can  be  used  when
engue  infection  is  discarded.  Patients  should  be  advised  to
rink  plenty  of  ﬂuids  to  replenish  ﬂuid  lost  from  sweating,
omiting,  and  other  insensible  losses.66
There  are  speciﬁc  guidelines  for  health  care  providers
aring  for  infants  and  children  with  possible  Zika  virus
nfection  at  the  ofﬁcial  CDC  website.  These  guidelines
ecommend  clinical  evaluation  and  laboratory  testing  for
nfants  with  possible  congenital  Zika  virus  infection,  with
r  without  microcephaly  or  intracranial  calciﬁcations.67
The  CDC  has  also  put  out  guidelines  for  health  care
roviders  caring  for  women  of  reproductive  age  with  pos-
ible  Zika  virus  exposure.  Women  who  have  had  Zika  virus
isease  or  exposure  without  clinical  illness,  should  wait  at
east  8  weeks  after  symptom  onset  to  attempt  conception.
en  with  Zika  virus  disease  should  wait  at  least  6  months
fter  symptom  onset,  or  8  weeks  after  exposure  to  the  virus
ithout  clinical  illness,  to  attempt  conception.  These  guide-
ines  also  provide  updated  recommendations  for  the  testing
f  pregnant  women  with  possible  Zika  virus  exposure.68 It  is
mportant  to  note  that  the  current  guidance  is  based  on  a
imited  body  of  evidence.
revention
ending  vaccine  development,  the  only  effective  preventive
easures  consist  of  individual  protection  against  mosquito
ites  and  vector  control.  Control  of  both  adult  and  larval
osquito  populations  uses  the  same  model  as  for  dengue
nd  has  been  relatively  effective  in  many  countries  and
ettings.  Mosquito  control  is  the  best  available  method  for
reventing  ZIKV  infection.  Breeding  sites  must  be  removed,
estroyed,  frequently  emptied,  and  cleaned  or  treated  with
nsecticides.43For  protection,  clothing  which  minimizes  skin  exposure
o  the  day-biting  vectors  is  advised.  Repellents  can  be
pplied  to  exposed  skin  or  to  clothing,  in  strict  accor-
ance  with  product  label  instructions.  Repellents  shouldK.A.  Galán-Huerta  et  al.
ontain  DEET  (N,  N-diethyl-3-methylbenzamide),  IR3535
3-[N-acetyl-N-butyl]-aminopropionic  acid  ethyl  ester)  or
caridin  (1-piperidinecarboxylic  acid,  2-(2-hydroxyethyl)-
-methylpropylester).  Mosquito  coils  or  other  insecticide
aporizers  may  also  reduce  indoor  biting.69
As  previously  mentioned,  the  correct  and  consistent  use
f  condoms  during  any  sexual  intercourse  is  encouraged  to
revent  the  sexual  transmission  of  the  Zika  virus.  Another,
lthough  difﬁcult,  option  is  sex  abstention  while  active  virus
ransmission  persists.36
accines
p  to  March,  2016  there  is  no  available  vaccine  against  the
ika  virus.  There  are  several  proposals  for  a  vaccine,  using
he  same  methodology  as  other  anti-ﬂaviviruses  vaccines70;
evertheless,  the  process  is  still  long.  There  are  ethical
ssues  involving  pregnant  women  and  the  ‘‘safe  use’’  of
accines,  which  are  still  a  barrier.71
uture directions
here  are  still  many  unanswered  questions  regarding  the
ika  virus  disease.  Clinical  and  epidemiological  studies  must
e  performed  to  describe  viral  dynamics  and  the  expansion
f  the  outbreak.  More  studies  are  needed  to  conﬁrm  the
uspected  association  between  ZIKV  infection  with  micro-
ephaly  and  Guillain--Barré  syndrome.  Research  must  be
one  to  identify  an  antiviral,  prophylactic,  or  immunother-
py  vaccine  as  well  as  diagnostic  ELISA  testing.
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